Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NLTX Neoleukin Therapeutics	$20.20 -4.3%	$20.39	$2.03 ▼ $14.36	$189.84M	1.11	50,104 shs	168,876 shs
PHAT Phathom Pharmaceuticals	$10.24 -2.2%	$9.29	$2.21 ▼ $19.71	$742.78M	0.45	1.08 million shs	845,139 shs
STOK Stoke Therapeutics	$18.21 +6.1%	$12.55	$5.35 ▼ $18.45	$940.87M	1.15	913,360 shs	1.97 million shs
TNGX Tango Therapeutics	$6.77 -2.2%	$5.89	$1.03 ▼ $12.02	$769.92M	1.64	1.83 million shs	1.02 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NLTX Neoleukin Therapeutics	-4.31%	-5.87%	-5.92%	+12.28%	-40.90%
PHAT Phathom Pharmaceuticals	-2.20%	+5.13%	+22.93%	+150.37%	-17.68%
STOK Stoke Therapeutics	+6.06%	+39.01%	+53.03%	+86.58%	+30.35%
TNGX Tango Therapeutics	-2.17%	+2.42%	+6.61%	+351.33%	-27.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	3.1046 of 5 stars	3.5	1.0	0.0	0.0	2.3	5.0	0.6
STOK Stoke Therapeutics	4.1339 of 5 stars	3.6	1.0	0.0	4.8	2.5	0.8	1.3
TNGX Tango Therapeutics	1.9473 of 5 stars	3.5	1.0	0.0	0.0	2.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	70.90% Upside
STOK Stoke Therapeutics	3.25	Buy	$25.17	38.20% Upside
TNGX Tango Therapeutics	3.00	Buy	$10.33	52.63% Upside

Current Analyst Ratings Breakdown

Latest NLTX, TNGX, STOK, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/6/2025	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $10.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
PHAT Phathom Pharmaceuticals	$55.25M	13.15	N/A	N/A	($5.72) per share	-1.79
STOK Stoke Therapeutics	$36.56M	27.30	N/A	N/A	$6.11 per share	2.98
TNGX Tango Therapeutics	$42.07M	17.90	N/A	N/A	$1.21 per share	5.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	N/A
STOK Stoke Therapeutics	-$88.98M	$0.79	21.42	N/A	N/A	26.25%	18.32%	15.48%	11/4/2025 (Estimated)
TNGX Tango Therapeutics	-$130.30M	-$1.33	N/A	N/A	N/A	-599.11%	-79.72%	-49.30%	N/A

Latest NLTX, TNGX, STOK, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/5/2025	Q2 2025	TNGX Tango Therapeutics	-$0.35	-$0.35	N/A	-$0.35	$6.41 million	$3.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35
STOK Stoke Therapeutics	N/A	6.98	8.41
TNGX Tango Therapeutics	N/A	4.75	4.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NLTX Neoleukin Therapeutics	52.37%
PHAT Phathom Pharmaceuticals	99.01%
STOK Stoke Therapeutics	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
NLTX Neoleukin Therapeutics	1.58%
PHAT Phathom Pharmaceuticals	23.00%
STOK Stoke Therapeutics	9.50%
TNGX Tango Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
PHAT Phathom Pharmaceuticals	110	70.94 million	54.63 million	Optionable
STOK Stoke Therapeutics	100	54.80 million	49.59 million	Optionable
TNGX Tango Therapeutics	90	111.26 million	102.92 million	Optionable

NLTX, TNGX, STOK, and PHAT Headlines

Recent News About These Companies

B. Riley Increases Earnings Estimates for Tango Therapeutics

August 15 at 2:06 AM | americanbankingnews.com

B. Riley Raises Earnings Estimates for Tango Therapeutics

August 14 at 8:02 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by XTX Topco Ltd

August 14 at 3:26 AM | marketbeat.com

Equities Analysts Set Expectations for TNGX FY2025 Earnings

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lift Earnings Estimates for TNGX

August 9, 2025 | marketbeat.com

Q3 EPS Estimate for Tango Therapeutics Lifted by Analyst

August 8, 2025 | marketbeat.com

Wedbush Forecasts Stronger Earnings for Tango Therapeutics

August 8, 2025 | americanbankingnews.com

Guggenheim Boosts Tango Therapeutics (NASDAQ:TNGX) Price Target to $10.00

August 7, 2025 | marketbeat.com

Tango (TNGX) Q2 Revenue Drops 52%

August 5, 2025 | fool.com

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2025 | zacks.com

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 5, 2025 | globenewswire.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 7.1% - What's Next?

August 2, 2025 | marketbeat.com

Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade

July 30, 2025 | zacks.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

July 29, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Up 3% - Should You Buy?

July 24, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.1% - Time to Buy?

July 18, 2025 | marketbeat.com

TNGX - Tango Therapeutics Inc News - Morningstar

July 16, 2025 | morningstar.comM

Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?

July 14, 2025 | zacks.com

Tango Therapeutics doses first patient in cancer drug combo trial

June 29, 2025 | uk.investing.com

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

June 27, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX, TNGX, STOK, and PHAT Company Descriptions

Neoleukin Therapeutics NASDAQ:NLTX

$20.20 -0.91 (-4.31%)

As of 08/14/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Phathom Pharmaceuticals NASDAQ:PHAT

$10.24 -0.23 (-2.20%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.58 +0.34 (+3.32%)

As of 08/15/2025 06:22 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Stoke Therapeutics NASDAQ:STOK

$18.21 +1.04 (+6.06%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$18.30 +0.09 (+0.49%)

As of 08/15/2025 07:44 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$6.77 -0.15 (-2.17%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.78 +0.01 (+0.07%)

As of 08/15/2025 04:59 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time